comprehensive -WSS

comprehensive

author：fashion 2025-10-01 06:01:20 - browse：94892

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Stoke drug shows lower activity against childhood epilepsy

WSS

Trump allegedly attempted to have surveillance video deleted: Special Counsel

Trump Jan. 6 attorney John Lauro is ex

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Biden will tout long

The UK government moves asylum

'The Exorcist' director William Friedkin dead at 87

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

Biden announces an advanced cancer research initiative

Hepatitis C has a cure — but many Americans still lack access to it

At least 12 people were injured in a blast at a port in northwest Turkey

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Alkermes shareholders re

NYC plans to house migrants on an island in the East River

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Interest rates are at a 22

leisure time

Why workplace violence is so common in health care

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Stoke drug shows lower activity against childhood epilepsy

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

knowledge

entertainment

focus

leisure time